News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivir AB (MVRBF): Interim Report, January – June 2014*


8/21/2014 8:32:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:

(STO:MVIR-B)

Financial summary for the second quarter

-- Net turnover totalled SEK 564.0 million (SEK 40.7 m), of which SEK 500.7 million was contributed by royalties for simeprevir. Revenues from Medivir’s own pharmaceutical sales totalled SEK 62.9 million, SEK 21.7 million of which derived from sales of Olysio and SEK 41.2 million from sales of other pharmaceuticals. The profit/loss after tax was SEK 327.8 million (SEK -63.7 m).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES